Sarita Rodriguez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sarita Rodriguez has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- David Esteban Rebellón Sanchez
Unidad de Inteligencia Artificial, Fundación Valle del Lili, Cali, Valle del Cauca, Colombia
3 shared publications - Fernando Rosso
Departamento de Infectología, Fundación Valle del Lili, Cali, Colombia
3 shared publications - Julio Llanos-Torres
Fundación Valle del Lili , Cali, Valle del Cauca , Colombia
2 shared publications - Alejandro Tejada Vega
Facultad de Ciencias de la Salud, Universidad Icesi, Cali, Colombia
1 shared publication - Ana Craviotto Vallejo
Hospital Universitario 12 de Octubre, Madrid, España
1 shared publication - Carolina Álvarez-Ortega
Value & Implementation, Global Medical & Scientific Affairs, MSD Spain, 28027 Madrid, Spain
1 shared publication
Latest Publications
- Open Access
- 4 June 2025
- Published by Sociedad Espanola de Quimioterapia in Revista Española de Quimioterapia
- Vol. 38 (4) , 287-293
Características epidemiológicas de pacientes con aislamientos de Enterobacterales productores de carbapenemasas-NDM en un hospital de alta complejidad
Introducción: Las Enterobacterias productoras de carbapenemasas (EPC) tipo New Delhi metalo-β-lactamasa (NDM) son un problema creciente de salud pública dada su rápida diseminación, su amplia resistencia a antimicrobianos y su incremento de morbimortalidad asociado. El objetivo de este estudio fue describir las características epidemiológicas de los pacientes con aislamientos de EPC tipo NDM (EPC-NDM). Métodos: Estudio descriptivo de pacientes con al menos un aislamiento de EPC-NDM entre el 1 de diciembre de 2022 y el 31 de diciembre de 2023. Los datos demográficos, clínicos y evolutivos se recopilaron a partir de las historias clínicas electrónicas. Resultados: Se identificaron EPC-NDM en 77 pacientes, de los cuales el 87% eran adultos y el 75,3% hombres. El 32,5% eran inmunosuprimidos. El 84,4% requirió ingreso hospitalario (60% en UCI) y el 66,2% fue sometido a cirugía. La mediana entre el ingreso y el primer aislamiento microbiológico de EPC-NDM fue de 18 días (RIC: 4-32 días). El microorganismo más frecuente fue Klebsiella pneumoniae (92,2%), seguido de Escherichia coli (4,2%), y Citrobacter freundii (4,2%). El 58,4% eran portadores de genes codificantes para carbapenemasas tipo NDM y OXA-48, el 40,3% solo de NDM y el 1,3% de NDM y VIM. El 45,5% fueron pacientes con muestras de colonización positiva para EPC-NDM, de los cuales el 31,4% desarrolló infección posterior. Del total de pacientes, el 24,7% había fallecido al finalizar el estudio. Conclusiones: Resulta fundamental identificar tempranamente a los pacientes portadores, fortalecer la vigilancia epidemiológica y molecular e implementar precozmente medidas de control para interrumpir la cadena de transmisión y proteger a los pacientes más susceptibles.
- 4 June 2025
- Published by Sociedad Espanola de Quimioterapia in Revista Española de Quimioterapia
- Vol. 38 (4) , 287-293
Open AccessCaracterísticas epidemiológicas de pacientes con aislamientos de Enterobacterales productores de carbapenemasas-NDM en un hospital de alta complejidad
Introducción: Las Enterobacterias productoras de carbapenemasas (EPC) tipo New Delhi metalo-β-lactamasa (NDM) son un problema creciente de salud pública dada su rápida diseminación, su amplia resistencia a antimicrobianos y su incremento de morbimortalidad asociado. El objetivo de este estudio fue describir las características epidemiológicas de los pacientes con aislamientos de EPC tipo NDM (EPC-NDM). Métodos: Estudio descriptivo de pacientes con al menos un aislamiento de EPC-NDM entre el 1 de diciembre de 2022 y el 31 de diciembre de 2023. Los datos demográficos, clínicos y evolutivos se recopilaron a partir de las historias clínicas electrónicas. Resultados: Se identificaron EPC-NDM en 77 pacientes, de los cuales el 87% eran adultos y el 75,3% hombres. El 32,5% eran inmunosuprimidos. El 84,4% requirió ingreso hospitalario (60% en UCI) y el 66,2% fue sometido a cirugía. La mediana entre el ingreso y el primer aislamiento microbiológico de EPC-NDM fue de 18 días (RIC: 4-32 días). El microorganismo más frecuente fue Klebsiella pneumoniae (92,2%), seguido de Escherichia coli (4,2%), y Citrobacter freundii (4,2%). El 58,4% eran portadores de genes codificantes para carbapenemasas tipo NDM y OXA-48, el 40,3% solo de NDM y el 1,3% de NDM y VIM. El 45,5% fueron pacientes con muestras de colonización positiva para EPC-NDM, de los cuales el 31,4% desarrolló infección posterior. Del total de pacientes, el 24,7% había fallecido al finalizar el estudio. Conclusiones: Resulta fundamental identificar tempranamente a los pacientes portadores, fortalecer la vigilancia epidemiológica y molecular e implementar precozmente medidas de control para interrumpir la cadena de transmisión y proteger a los pacientes más susceptibles.
- Open Access
- 11 March 2024
- Published by Elsevier in The Brazilian Journal of Infectious Diseases
- Vol. 28 (2) , 103737
Navigating the waves in Colombia: a cohort study of inpatient care during four COVID-19 waves
- 11 March 2024
- Published by Elsevier in The Brazilian Journal of Infectious Diseases
- Vol. 28 (2) , 103737
Open AccessNavigating the waves in Colombia: a cohort study of inpatient care during four COVID-19 waves
- Open Access
- 27 November 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (Supplement)
440. Steroid Use and Elevated Rates of Coinfections and Mortality in Mild-COVID-19 Patients
Systemic corticosteroids are used to treat patients with COVID-19. Since the findings of the RECOVERY trial, steroids have been broadly used in critical patients. However, their use in patients with mild disease was unclear and may even be harmful. In the hard times of the pandemic in the absence of widely available vaccines or antivirals agents, hospital overcrowding, patients had to be referred to home care and steroids could be overused. The aim of this study was to explore the relationship between the use of corticosteroids, secondary infections and overall mortality in adults with COVID-19 A prospective observational study was performed in a university hospital in Cali, Colombia. Severity was assessed with NEWS score 2. The study included patients at various levels of severity, including patients admitted to the emergency department, inpatients, and those admitted to the intensive care unit A total of 12,227 patients were treated at our hospital during the first four waves of the pandemic. 54.8% were female, with median age of 45 years (IQR: 31 - 62). 68.5% were classified as mild COVID-19, 8.8% as moderate, and 22.68% as severe. 5.49% of patients were pregnant. Of all patients, 24.30% received corticosteroids upon admission, 11.6% developed secondary infections, and 8.4% died. Mild COVID-19 cases were 1,988 (wave 1), 2,147 (wave 2), 1,628 (wave 3), and 1,608 (wave 4). The proportions of corticosteroid used by waves were 4.3%, 7.18%, 12.5%, and 8.1%, respectively. Corresponding proportions for secondary infections were 2.80%, 5.26%, 6.14%, and 3.8%, while death proportions were 1.7%, 2.5%, 3.2%, and 2.1%. A positive correlation was found between corticosteroid use and secondary infection and mortality rates (Fig. 1). Correlation coefficients were r= 0.9 (p= 0.09) for corticosteroid use and mortality, r= 0.84 (p= 0.15) for corticosteroid use and secondary infection, and r= 0.94 (p= 0.01) for secondary infection and mortality. These correlations were not observed in moderate and severe COVID-19 cases A. Relationship in mild COVID-19 patients. B. Relationship in moderate-to-severe COVID-19 patients Our study shows that the use of corticosteroids in mild cases could correlate with a greater proportion of secondary infections and mortality All Authors: No reported disclosures
- 27 November 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (Supplement)
Open Access440. Steroid Use and Elevated Rates of Coinfections and Mortality in Mild-COVID-19 Patients
Systemic corticosteroids are used to treat patients with COVID-19. Since the findings of the RECOVERY trial, steroids have been broadly used in critical patients. However, their use in patients with mild disease was unclear and may even be harmful. In the hard times of the pandemic in the absence of widely available vaccines or antivirals agents, hospital overcrowding, patients had to be referred to home care and steroids could be overused. The aim of this study was to explore the relationship between the use of corticosteroids, secondary infections and overall mortality in adults with COVID-19 A prospective observational study was performed in a university hospital in Cali, Colombia. Severity was assessed with NEWS score 2. The study included patients at various levels of severity, including patients admitted to the emergency department, inpatients, and those admitted to the intensive care unit A total of 12,227 patients were treated at our hospital during the first four waves of the pandemic. 54.8% were female, with median age of 45 years (IQR: 31 - 62). 68.5% were classified as mild COVID-19, 8.8% as moderate, and 22.68% as severe. 5.49% of patients were pregnant. Of all patients, 24.30% received corticosteroids upon admission, 11.6% developed secondary infections, and 8.4% died. Mild COVID-19 cases were 1,988 (wave 1), 2,147 (wave 2), 1,628 (wave 3), and 1,608 (wave 4). The proportions of corticosteroid used by waves were 4.3%, 7.18%, 12.5%, and 8.1%, respectively. Corresponding proportions for secondary infections were 2.80%, 5.26%, 6.14%, and 3.8%, while death proportions were 1.7%, 2.5%, 3.2%, and 2.1%. A positive correlation was found between corticosteroid use and secondary infection and mortality rates (Fig. 1). Correlation coefficients were r= 0.9 (p= 0.09) for corticosteroid use and mortality, r= 0.84 (p= 0.15) for corticosteroid use and secondary infection, and r= 0.94 (p= 0.01) for secondary infection and mortality. These correlations were not observed in moderate and severe COVID-19 cases A. Relationship in mild COVID-19 patients. B. Relationship in moderate-to-severe COVID-19 patients Our study shows that the use of corticosteroids in mild cases could correlate with a greater proportion of secondary infections and mortality All Authors: No reported disclosures
- Open Access
- 6 September 2023
- Published by American Society of Tropical Medicine and Hygiene in The American Journal of Tropical Medicine and Hygiene
- Vol. 109 (3) , 536-541
Co-Infection between Dengue Virus and SARS-CoV-2 in Cali, Colombia
: The co-occurrence of COVID-19 with endemic diseases is a public health concern that may affect patient prognosis and outcomes. The objective of this study was to describe the clinical characteristics of patients with dengue virus (DENV) and SARS-CoV-2 co-infections and compare their outcomes against those of COVID-19 patients without dengue. A cross-sectional study was conducted in patients with SARS-CoV-2 infection who attended a single center in Cali, Colombia, from March 2020 to March 2021. All patients who were tested by both real-time polymerase chain reaction for SARS-CoV-2 and IgM/NS1 for DENV were included. Dengue was diagnosed as having either an IgM- or an NS1- positive test. A total of 90 patients were included (72 with COVID-19 only and 18 with co-infection). Patients with co-infection had more dyspnea (61.1% versus 22.2%; P = 0.003) as well as higher oxygen desaturation (53.3% versus 13.4%; P = 0.002) and neutrophil-to-lymphocyte ratio (5.59 versus 3.84; P = 0.038) than patients with COVID-19 alone. The proportion of patients classified with moderate to severe COVID-19 was higher in the co-infection group (88.3% versus 47.8%; P = 0.002). Also, co-infection was associated with an increased need for mechanical ventilation (P = 0.06), intensive care unit (ICU) initial management (P = 0.02), and ICU admission during hospitalization (P = 0.04) compared with COVID-19 only. The ICU mortality rate was 66.6% in patients with co-infection versus 29.4% in patients infected with only SARS-CoV-2 (P < 0.05). The possibility of DENV and SARS-CoV2 co-infection occurred in the convergence of both epidemic waves. Co-infection was associated with worse clinical outcomes and higher mortality in ICU-admitted patients than in patients with the COVID-19 only.
- 6 September 2023
- Published by American Society of Tropical Medicine and Hygiene in The American Journal of Tropical Medicine and Hygiene
- Vol. 109 (3) , 536-541
Open AccessCo-Infection between Dengue Virus and SARS-CoV-2 in Cali, Colombia
: The co-occurrence of COVID-19 with endemic diseases is a public health concern that may affect patient prognosis and outcomes. The objective of this study was to describe the clinical characteristics of patients with dengue virus (DENV) and SARS-CoV-2 co-infections and compare their outcomes against those of COVID-19 patients without dengue. A cross-sectional study was conducted in patients with SARS-CoV-2 infection who attended a single center in Cali, Colombia, from March 2020 to March 2021. All patients who were tested by both real-time polymerase chain reaction for SARS-CoV-2 and IgM/NS1 for DENV were included. Dengue was diagnosed as having either an IgM- or an NS1- positive test. A total of 90 patients were included (72 with COVID-19 only and 18 with co-infection). Patients with co-infection had more dyspnea (61.1% versus 22.2%; P = 0.003) as well as higher oxygen desaturation (53.3% versus 13.4%; P = 0.002) and neutrophil-to-lymphocyte ratio (5.59 versus 3.84; P = 0.038) than patients with COVID-19 alone. The proportion of patients classified with moderate to severe COVID-19 was higher in the co-infection group (88.3% versus 47.8%; P = 0.002). Also, co-infection was associated with an increased need for mechanical ventilation (P = 0.06), intensive care unit (ICU) initial management (P = 0.02), and ICU admission during hospitalization (P = 0.04) compared with COVID-19 only. The ICU mortality rate was 66.6% in patients with co-infection versus 29.4% in patients infected with only SARS-CoV-2 (P < 0.05). The possibility of DENV and SARS-CoV2 co-infection occurred in the convergence of both epidemic waves. Co-infection was associated with worse clinical outcomes and higher mortality in ICU-admitted patients than in patients with the COVID-19 only.